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1Synthesis and Conformational Analysis of 18-membered Aib-
Containing Cyclohexapeptides
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Institute of Organic Chemistry, University of Zürich, Winterthurerstrasse 190,
CH-8057 Zürich, Switzerland
Abstract  The synthesis and conformational analysis of two Aib-containing cyclic
hexapeptides, cyclo(Gly-Aib-Leu-Aib-Phe-Aib) 1 and cyclo(Leu-Aib-Phe-Gly-
Aib-Aib) 2, is described. The linear precursors of 1 and 2 were prepared using
solution phase techniques, and the cyclization efficiency of three different
coupling reagents (HATU, PyAOP, DEPC) was examined. The success of the
cyclization was found to be reagent dependent. Solid-state conformational
analysis of 1 and 2 was performed by X-ray crystallography and has revealed
some unusual features as all three Aib residues of 1 assume nonhelical
conformations. Furthermore, the residue Aib4 adopts an extended conformation (φ
= -175.9(3)°, ψ = +178.6(2)°), which is, to the best of our knowledge, the first
observation of an Aib residue adopting an extended conformation in a
cyclopeptide. The structure of 1 is also a rare example in which an Aib residue
occupies the (i+1) position of a type II’ β-turn, stabilized by a bifurcated hydrogen
bond. The cyclic peptide 2 adopts a more regular conformation in the solid state,
consisting of two fused β-turns of type I/I’, stabilized by a pair of intramolecular
hydrogen bonds. In addition, the conformational study of the cyclic peptide 1 in
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2DMSO-d6 by NMR spectroscopy and molecular dynamics simulations revealed a
structure which is very similar to its structure in the crystalline state.
1.  Introduction
Cyclic peptides continue to be challenging targets for chemical synthesis.1 As the
synthesis of linear peptides generally proceeds well, the key step for the chemical
synthesis of cyclic peptides is usually the cyclization reaction. In particular, the
cyclization of small peptides of less than seven amino acid residues is often
difficult.2 Incorporation of turn-inducing elements such as Gly, Pro, D-amino
acids and N-alkylated amino acids into the peptide backbone is known to improve
cyclization yields.3 Although conformational constraints are usually introduced
into peptides through cyclization, cyclic peptides can still possess a remarkable
flexibility.4, 5 Thus, the incorporation of sterically hindered C(2)-tetrasubstituted
α-amino acids into the peptide backbone leads to more rigid compounds. In
addition, cyclic penta- and hexapeptides are often chosen for the synthesis of
model cyclopeptides, since larger cyclic peptides already exhibit greater
flexibility.6 Conformation-constrained cyclic peptides may have enhanced
metabolic stability, receptor selectivity, and bioavailability, all of which may lead
to useful medicinal properties.
Our previous successful synthesis of cyclic hexapeptides containing several Aib
(α-aminoisobutyric acid) residues and two Gly residues in positions 1 and 4 of the
peptide backbone7,8 prompted us to investigate the cyclization of hexapeptides
containing only one Gly residue as the turn-inducing element. Here, we describe
the synthesis of two cyclic hexapeptides cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1) and
cyclo(Leu-Aib-Phe-Gly-Aib-Aib) (2), composed of three protein amino acids, i.e.
Gly, Leu, Phe and three α-aminoisobutyric acids. The crystal structures of both
3cyclic peptides were examined by X-ray diffraction in order to study the influence
of the Aib residues on the conformation of the backbone of the cyclic
hexapeptides. A NMR-based structure determination of 1 in solution was also
performed in the present study.
Formulae
2.  Results and Discussion
2.1.  Preparation and Cyclization of Linear Hexapeptides.
The linear hexapeptides Z-Gly-Aib-Leu-Aib-Phe-Aib-OtBu (5) and Z-Leu-Aib-
Phe-Gly-Aib-Aib-N(Me)Ph (8) were synthesized by solution-phase methods as
shown in Schemes 1 and 2. A [2+2+2]-fragment condensation was chosen in the
case of 5. At first, the dipeptide Z-Phe-Aib-OtBu (3) was prepared by coupling Z-
Phe-OH with HCl•H-Aib-OtBu using PyAOP as the coupling reagent. Then, 3
was N-deprotected to give H-Phe-Aib-OtBu by means of catalytic hydrogenation.
The PyAOP-mediated coupling of the latter with Z-Leu-Aib-OH9 afforded
tetrapeptide Z-Leu-Aib-Phe-Aib-OtBu (4) in high yield. Removal of the Z
protecting group of 4, and coupling of the resulting H-Leu-Aib-Phe-Aib-OtBu
with Z-Gly-Aib-OH in the presence of PyAOP afforded the linear hexapeptide 5.
Scheme 1
For the synthesis of the linear hexapeptide 8, a convergent [3+3] strategy was
employed. Thus, the tripeptide Z-Leu-Aib-Phe-OtBu (6) was prepared by
coupling Z-Leu-Aib-OH with the hydrochloride of H-Phe-OtBu using PyBOP as
the coupling reagent. Treatment of 6 with TFA in CH2Cl2, followed by the
4reaction with H-Gly-Aib-Aib-N(Me)Ph, which was obtained by deprotection of Z-
Gly-Aib-Aib-N(Me)Ph (7),6 led, in the presence of PyAOP, to the hexapeptide 8
in moderate yield.
Scheme 2
The linear hexapeptides Z-Gly-Aib-Leu-Aib-Phe-Aib-OtBu (5) and Z-Leu-Aib-
Phe-Gly-Aib-Aib-N(Me)Ph (8) were then deprotected at the N- and C-terminus
and treated with the coupling reagents HATU, PyAOP and DEPC to investigate
the cyclization tendency of each peptide. All of the cyclization reactions were
performed in diluted DMF solutions (10-4-10-3 M) using a large excess of coupling
reagent and base (DIEA). The yields of the cyclization reactions are shown in
Table 1. In the first attempts we used HATU as the activating agent, since it has
proven to be versatile and highly efficient.2 However, the cyclohexapeptides 1 and
2 were obtained only in relatively low yields. One explanation for the less
efficient macrolactamization than expected could be that HATU participated in a
side reaction at the amino terminus to give a guanidino derivative. This side
reaction is known to occur when an excess of the aminium salt based coupling
reagents is used.10 To avoid this problem, phosphonium reagents such as PyBOP
and PyAOP are recommended.11 Thus, PyAOP together with HOAt was
employed in the cyclization step, leading to 1 in moderate yield while 2 was
obtained in good yield. Next, the macrolactamization ability of the
organophosphorus reagent DEPC was tested. Because of the slower reaction rate
under the DEPC/DIEA conditions, reaction times of up to six days were used.
This time, the cyclic hexapeptide 1  was obtained in good yield, while
cyclopeptide 2 was isolated in moderate yield. As is evident from these results,
the success of the cyclization is dependent upon the choice of the cyclization
5reagent. However, 1 and 2 were obtained in remarkably similar overall moderate
(30%) to good yields (50%). Comparing the best cyclization protocols for 1 and 2
it was surprising that the lactamization between the less hindered pair H2N-Gly
and Aib-CO proceeded only slightly better than that between NH2 of the sterically
demanding Leu residue and Aib-CO. It appears that the conformation or (and)
sequence of the linear precursor played a more important role than the size of the
residue at the N-terminus.
Table 1
The cyclic structures of 1 and 2 were established by standard two-dimensional
NMR techniques. The assignment of all H- and C-signals was possible by using
2D HSQC and HMBC spectra. A combination of these two types of spectra
allowed the complete assignment of the amide NH, CO and C(α) signals of all
residues, as well as enabling the signals of different Aib residues to be
distinguished. In addition, selected ROESY correlations observed in DMSO-d6
solution are shown in Fig. 1.
Fig. 1
2.2.  Solid state conformation.
Cyclic peptides are frequently found among natural products and exhibit a wide
range of biological activities. Therefore, their conformations have been studied
extensively both in the solid state and in solution, since the chemical properties
and biological activities of such structures are known to be closely related to their
molecular conformation. The crucial determinantes of the conformation of cyclic
peptides are the turns (β , γ) and intramolecular hydrogen bonds. Cyclic
6hexapeptides have been used as model peptides for β-turns since these peptides,
due to geometric factors, generally adopt a conformation with two β-turns,
stabilized by a pair of two intramolecular hydrogen bonds between residues i and
i+3.12 Turns do not necessarily contain hydrogen bonds, but the lack of hydrogen
bonds generally results in distorted or unstable structures.
By extensive crystallographic studies, α-amino isobutyric acid (Aib) has been
shown to favor left- or right-handed 310/α-helical conformations in a wide variety
of acyclic peptides of differing lengths and sequences.13-16 Indeed, Aib residues
with very few exceptions almost invariably adopt conformations with φ and ψ
values near ±(60±20)° and ±(30±20)°, respectively. In addition, theoretical
calculations show the presence of minima in a semiextended region of the φ, ψ
space (φ = ±(60±20)°, ψ = ±(120±20)°).13
There are relatively few reports concerning crystallographic studies of Aib
residues incorporated into cyclic peptides,17-21 so the structural information about
the conformational preferences of Aib residues in cyclic molecules is rather
scarce. The cyclic tetrapeptide dehydrochlamydocin17 and the cyclic pentapeptide
cyclo(Phe-Phe-Aib-Leu-Pro)18 both have the Aib residue at the center of a γ-turn
with unexpected values of the torsion angles φ, ψ  that lie in the nonhelical
conformational space. The torsion angles (φ,ψ) of the Aib residues in the crystal
structures of cyclo(Gly-Aib-Gly)2,
19 [Aib5,6-D-Ala8]cyclolinopeptide A,20 and
cyclo(Pro-Phe-Phe-Aib-Leu)2
21 all lie well inside the 310/α-helical region of the
conformational space, as is observed in linear peptides.
In our research group, we have synthesized several Aib-containing
cyclopentapeptides,15,16 and the crystal-structures of three of them have been
established by X-ray crystallography. The structures of cyclo[Gly-(RS)-Phe(2Me)-
Aib-Aib-Gly]15 and cyclo[Gly-Aib-(RS)-Phe(2Me)-Aib-Gly]16 are very similar
and have a β-turn, which is stabilized by a hydrogen bond between NH of Gly1
7and CO of Phe(2Me)3 and CO of Aib3, respectively. Whereas in both structures
the torsion angles of Aib4 show values typical for the helical region, those of Aib3
and Aib2, respectively, do not correspond with the helical conformational space.
In the asymmetric unit of the crystal structure of the third cyclopentapeptide, i.e.
cyclo[Gly-(R)-Phe(2Me)-Pro-Aib-Phe],16 there are two independent molecules
with quite different conformations. One of the molecules forms a β-turn with a
Aib4→Gly1 hydrogen bond, whereas the other molecule is characterized by a γ-
turn (NH(Aib4)→CO(Pro3) hydrogen bond) and an α-turn (NH(Phe5)-CO(Gly1)
hydrogen bond). In both molecules, Aib4 shows φ,ψ values that belong to the
nonhelical conformational space.
As a part of our investigation of the synthesis of cyclic hexapeptides containing
Aib residues,6, 22 we have been interested in the conformations of these cyclic
molecules in order to estimate if the incorporation of several Aib residues into
cyclic hexapeptide structures stabilizes certain types of turns. Previously, we have
investigated the cyclization and conformation of hexapeptides containing two or
three Aib residues, and two Gly residues in positions 1 and 4 of the peptide
backbone.6 The crystal structures of two cyclic peptides, cyclo(Gly-Aib-Aib-Gly-
Aib-Phe) and cyclo(Gly-(S)-Phe(2Me)-Aib-Gly-Aib-Phe), showed that these
molecules have two fused β-turns. The observed β-turns were stabilized by
intramolecular hydrogen bonds between the NH of Gly1 and the C=O of Gly4 and
between the NH of Gly4 and C=O of Gly1. Different types of β-turn
conformations, i.e. I, I’ and III’, have been observed depending on the sequence,
with Aib residues occupying positions (i+1) and/or (i+2) of the turns.
The solid-state conformations of the new cyclohexapeptides cyclo(Gly-Aib-Leu-
Aib-Phe-Aib) (1) and cyclo(Leu-Aib-Phe-Gly-Aib-Aib) (2) were examined by X-
ray crystallography. Crystals of 1 suitable for the X-ray analysis were obtained
from a mixture of MeOH/i-PrOH/CHCl3 and acetone, and those of 2 were grown
8from MeOH/EtOH/i-PrOH and water. The ORTEP plots23 of the molecules with
the atom numbering schemes are presented in Figs. 2 and 3. The isopropyl part of
the Leu side chain of 1  is disordered over two almost equally occupied
conformations (Fig. 2), while the asymmetric unit of 2 contains one molecule of
the cyclic peptide plus two water molecules, one disordered EtOH molecule and
one disordered i-PrOH molecule. Two approximately equally occupied positions
were modelled for each of the disordered solvent molecules (Fig. 3). The
backbone torsion angles of the cyclopeptides are summarized in Table 2 and the
hydrogen bonding parameters in Tables 3 and 4.
Fig. 2
Fig. 3
Surprisingly, all three Aib residues of cyclo(Gly1-Aib2-Leu3-Aib4-Phe5-Aib6) (1)
assume conformations in the nonhelical region of the Ramachandran diagram
(Table 2). The deviation of the backbone conformation from the helical region is
less pronounced at Aib6. The residue Aib2 adopts a rare semiextended
conformation with torsion angles φ, ψ  almost identical to those previously
reported for a cyclic hexapeptide having a disulfide linkage.24 Interestingly, very
similar φ , ψ  values were also observed for one Aib residue in the linear
tetrapeptide Boc-Leu-Aib-Phe-Aib-OMe, which was reported to form a
continuous hydrogen-bonded supramolecular helix.25 The residue Aib4 adopts a
fully extended conformation, so far known to be characteristic of the higher
homologs of Aib, like α ,α-diethylglycine (Deg),26-28 and α ,α-dipropylglycine
(Dpg).29, 30 The torsion angles φ and ψ of the Phe and Aib6 residues in the Aib4-
Phe5-Aib6-Gly1 sequence show values close to those for a type II β-turn with an
9intramolecular 1←4 hydrogen bond (N(1)-H…O(12)) involving the NH of Gly1
and the C=O of Aib4 (Tables 2 and 3). In contrast, the backbone conformation of
the sequence Gly1-Aib2-Leu3-Aib4 cannot be strictly categorized. It could best be
described as a distorted type II’ β-turn, with values for φi+1 (+55.2(3)°), ψi+1 (-
130.4(3)°) and φi+2 (-90.7(3)°) being close to the ideal values (φi+1 = +(60±30)°;
ϕi+1 = -(120±30)°, φi+2 = -(80±30)°) for this type of turn, and ψi+2 (+42.6(3)°)
deviating largely from the ideal value (ψi+2 = 0±50°) (Table 2). The residue Aib
2
is obviously forced to assume the conformation of a D-amino acid as it prefers the
(i+1) position of a β-turn of type II’.12 As a consequence of the large deviation of
ψi+2 from ideality, no 1←4 intramolecular hydrogen bond is observed between the
NH of Aib4 and C=O of Gly1. However, the extended conformation of Aib4 gives
rise to an intramolecular hydrogen bond between the NH and C=O groups within
this residue (N(10)-H…O(12), Table 3), which is unusual and has only
infrequently been inferred from crystal structure data of some dipeptides.13
Furthermore, the NH group of Aib4 acts not only as a donor for C=O of Aib4, but
also as a donor for the carbonyl group of Aib2, and is thus involved in inverse
bifurcation.31
Table 2
Table 3
The cyclic peptide cyclo(Leu1-Aib2-Phe3-Gly4-Aib5-Aib6) (2 ) was found to
possess a more regular structure with two fused β-turns stabilized by two
intramolecular hydrogen bonds, one between C=O of Leu1 and NH of Gly4
(N(10)-H…O(3), Table 4) and the other between C=O of Gly4 and NH of Leu1
(N(1)-H…O(12)). Furthermore, the conformation of only one of the Aib residues,
10
Aib6, shows slight deviation from the helical region of the conformational space.
The values of torsion angles φ and ψ reveal the presence of a type I β-turn across
Leu1-Aib2-Phe3-Gly4 and a type I’ β-turn spanning the residues Gly4-Aib5-Aib6-
Leu1 (Table 2).
Table 4
2.3.  Solution Conformational Analysis.
The conformation of the cyclic hexapeptide cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1)
in DMSO-d6 solution has been determined by 
1H NMR spectroscopy. The
structure calculation was performed by restrained molecular dynamics in torsion
angle space by applying the simulated annealing protocol implemented in the
program DYANA.32 The NOE intensities were calibrated with the tools of the
program, and yielded an input of 45 upper-distance limits (11 intra-residual, 29
sequential and 5 medium/long-range) (Tables 6-8). The final calculation was
started with 100 randomized conformers, and a bundle of 20 DYANA conformers
with the lowest target function was selected for structure analysis and
visualisation with the program MOLMOL.33 The results of DYANA calculations
for 1 are shown in Fig. 4, and the observed average backbone torsion angles (φ, ψ)
are listed in Table 5.
Fig. 4
Table 5
As is evident from Fig. 4 and Table 5, 1 is well structured in solution and with a
mean RMSD value of the backbone atoms of 0.3 Å very similar to the backbone
11
conformation found in the crystal structure, although some torsion angles deviate
significantly. In particular, the residue Aib4 assumes almost identical, for an Aib
residue unexpected, extended conformations in both the solid state and in the
solution. The average conformer exhibits two β-turns, one type I-like β-turn
centered at Aib2-Leu3 and one type II-like β-turn across Aib4-Phe5-Aib6-Gly1. The
large 3J(HN, HC(α)) coupling constant of ca. 9 Hz at Leu3 which correlates to a
torsion angle ψ around –100° provide further support for the occurrence of the
type I β-turn in solution. An analysis of the hydrogen-bonding patterns using the
final NMR coordinates shows a significant population of intramolecular hydrogen
bonding between the carbonyl group of Gly1 and the NH of the Aib4 residue,
which is contrary to the observation found in the crystal structure where a
hydrogen bond is formed between the CO group of Aib4 and the NH group of
Gly1.
Table 6
Table 7
Table 8
3. Conclusion
In conclusion, we have shown that it is possible to cyclize hexapeptides
containing three constrained Aib residues, two rather large proteinogenic amino
acid residues (Leu, Phe) and only one Gly residue as a turn-inducing element, in
good yields. Since cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1) and cyclo(Leu-Aib-Phe-
Gly-Aib-Aib) (2) have been obtained in similar overall cyclization yields, being
24-53% for 1 and 16-48% for 2, the choice of coupling reagent apparently played
12
a more important role in the cyclization than the sequence of the linear precursor.
In addition, the coupling reagents PyAOP and DEPC proved to be superior to
HATU. The structures of 1 and 2 were examined in the solid state by X-ray
crystallography in order to gain information about the conformational preferences
of Aib residues incorporated into cyclic peptides. A detailed comparison of the
crystal structures of 1 and 2 with those obtained previously for cyclo(Gly-Aib-
Aib-Gly-Aib-Phe) and cyclo(Gly-(S)-Phe(2Me)-Aib-Gly-Aib-Phe), reveals severe
conformational restraints imposed on the peptide backbone of cyclic hexapeptide
1 consisting of alternating Aib and proteinogenic amino acid residues. Thus, all
three Aib residues of 1 assume torsion angles well outside the helical region of the
conformational space, which is highly uncommon. It appears that the
conformational constraint is less pronounced in the other three cyclopeptides
having two adjoining Aib residues or one Aib residue adjacent to another α,α-
disubstituted amino acid residue such as Phe(2Me) (Phe(2Me) = α-
methylphenylalanine). Each of these cyclic hexapeptides possesses only one Aib
residue that shows slight deviation of torsion angles from the helical region of the
conformational space.
4.  Experimental
4.1.  General
Solvents were purified by standard procedures. Thin-layer chromatography
(TLC): Merck TLC aluminium sheets, silica gel 60 F254. Column chromatography
(CC): Uetikon-Chemie ’Chromatographiegel’ C-560. M.p: Büchi 510 apparatus;
uncorrected. IR Spectra: Perkin-Elmer-1600 FT-IR spectrophotometer; in KBr;
absorptions in cm-1. 1H- (300 MHz) and 13C-NMR (75.5 MHz) spectra: Bruker
13
ARX-300 instrument; 1H- (600 MHz) and 13C-NMR (150.9 MHz) spectra of cyclic
peptides: Bruker DRX-600 instrument; in (D6)DMSO at 300 K unless otherwise
stated; δ in ppm, coupling constants J in Hz. MS: Finnigan SSQ-700 or MAT-90
instrument for CI; Finnigan TSQ-700 triple quadrupole spectrometer for ESI; m/z
(rel.%). Abbreviations: DEPC: diethylphosphorocyanidate, DIEA: N-ethyl-N,N-
d i i s o p r o p y l a m i n e ,  H A T U :  O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate, HOAt: 1-hydroxy-7-azabenzotriazole,
PyAOP: (7-azabenzotriazol-1-yloxy)tris(pyrrolidino)phosphonium
hexafluorophosphate, PyBOP: (1H-benzotriazol-1-yloxy)tris(pyrrolidino)
phosphonium hexafluorophosphate.
General Procedure A (GP A). To a solution of a Z-protected peptide in MeOH
was added Pd/C (10% on activated charcoal) and the mixture was hydrogenated
overnight under atmospheric pressure using an H2-filled balloon. The catalyst was
removed by filtration through a pad of celite and the solvent evaporated under
reduced pressure. The crude product was further purified by filtration through a
short column of SiO2, dried under vacuum and used directly in the next reaction
step.
General Procedure B (GP B). To a solution of an N-protected peptide acid (or N-
protected amino acid) in abs. CH2Cl2 (or CH2Cl2/MeCN mixture) were added the
amino component (1.0 or 1.1 equiv.), PyAOP (or PyBOP, 1.1 equiv.), and DIEA
(2 equiv. without and 3 equiv. with hydrochloride salts present). The mixture was
stirred at rt under N2 until the starting material was consumed (TLC). The solvent
was then evaporated, the residue was dissolved in EtOAc and washed with 5% aq.
KHSO4 solution, 5% aq. NaHCO3 solution and brine. The organic layer was dried
(MgSO4), concentrated, purified by CC and dried under high vacuum.
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General Procedure C (HATU-mediated Cyclization) (GP C). The free linear
hexapeptide was dissolved in abs. DMF (0.7 or 1.5 mM) and cooled to 0 °C in an
ice bath. To the solution was added HATU (3 equiv.), HOAt (3 equiv., 0.5 M
solution in DMF) and DIEA (1% v/v) under stirring. The solution was kept at 0 °C
for 2 h and at rt for 3 d. The solvent was removed under reduced pressure, the
residue dissolved in EtOAc and washed with 1M HCl solution, water, and brine.
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated.
The crude cyclopeptide was further purified by CC.
General Procedure D (DEPC-mediated Cyclization) (GP D). The free linear
hexapeptide was dissolved in abs. DMF (1.5 mM) and the solution was cooled to 0
°C in an ice bath. Then, a solution of 5 equiv. of DEPC in abs. DMF (1 ml) was
added under stirring, and DIEA (1% v/v) was added slowly over a period of 15
min. The solution was warmed to rt and stirred. The addition of DEPC  (2.5
equiv.) was repeated after 2 and 4 d, and the reaction mixture was stirred for an
additional 2 d. The solvent was then evaporated under reduced pressure, the
residue was taken up in EtOAc and washed with 5% aq. KHSO4 solution, 5% aq.
NaHCO3 solution, and brine. The organic phase was then dried (MgSO4) and
concentrated to give the crude cyclohexapeptide, which was purified by CC.
General Procedure E (PyAOP-mediated Cyclization) (GP E). The free linear
hexapeptide was dissolved in abs. DMF (0.6-1.0 mM) under stirring. Then,
PyAOP (3 or 5 equiv.), HOAt (3 or 5 equiv., 0.5 M solution in DMF) and DIEA
were added at r.t. and the solution was stirred at rt for an additional 3 d. The
solvent was then removed under reduced pressure, the residue dissolved in EtOAc
and washed with 10% citric acid solution, 5% NaHCO3 solution, and water. The
organic layer was dried (Na2SO4), filtered, and concentrated to afford a yellow oil
which was purified by CC.
4.2. Preparation of Cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1).
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4.2.1. tert-Butyl N-[(Benzyloxy)carbonyl]-(S)-phenylalanyl-dimethylglycinate
(Z-Phe-Aib-OtBu) (3).
Z-Phe-OH (0.6 g, 2.0 mmol) was coupled with HCl•H-Aib-OtBu (0.431 g, 2.2
mmol), using PyAOP (1.147 g, 2.2 mmol) and DIEA (0.775 g, 6.0 mmol) in
CH2Cl2/MeCN (6 ml/4 ml) according to GP B. Reaction time: 20 h at rt.
Purification of the crude product by CC (SiO2, EtOAc/hexane 15:10) afforded
0.798 g (91%) of dipeptide 3. White powder. M.p. 119.5-121.0 °C. IR: 3325s,
3236m, 3065m, 2979m, 2948m, 1727s, 1708s, 1660s, 1544s, 1498m, 1470m,
1455m, 1384m, 1370m, 1291s, 1260s, 1235s, 1215m, 1147s, 1085w, 1065m,
1044m, 1028m, 912w, 853w, 757m, 740m, 700s. 1H-NMR: 8.23 (s, NH of Aib);
7.42 (d, J = 8.95, NH of Phe); 7.34-7.19 (m, 10 arom. H); 4.94 (br. s, PhCH2O);
4.35-4.20 (m, CH(2) of Phe); 2.93-2.92, 2.77-2.73 (2m, CH2(3) of Phe); 1.35 (s,
Me3C); 1.33, 1.30 (2s, 2 Me of Aib). 
13C-NMR: 172.7, 170.6 (2s, 2 CO); 155.6 (s,
CO (urethane)); 138.0, 136.9 (2s, 2 arom. C); 129.1, 128.1, 127.8, 127.5, 127.2,
126.1 (6d, 10 arom. CH); 79.3 (s, Me3C); 64.9 (t, PhCH2O); 55.6 (d, C(2) of Phe);
55.3 (s, C(2) of Aib); 37.6 (t, C(3) of Phe); 27.3 (q, Me3C); 24.6 (q, 2 Me of Aib).
ESI-MS (NaI+MeOH): 463 (100, [M+Na]+). Anal. calc. for C25H32N2O5 (440.54):
C 68.16, H 7.32, N 6.36; found: C 68.06, H 7.20, N 6.25.
4.2.2. tert-Butyl N-[(Benzyloxy)carbonyl]-(S)-leucyl-dimethylglycyl-(S)-
phenylalanyl-dimethylglycinate (Z-Leu-Aib-Phe-Aib-OtBu) (4).
Z-Phe-Aib-OtBu (3) (0.475 g, 1.08 mmol) was N-deprotected by following GP A
(H2, 55 mg Pd/C, 15 ml MeOH, overnight). The crude product was filtered
through a short SiO2-column with EtOAc/MeOH (15:1) and dried under vacuum
to give 0.328 g (99%) H-Phe-Aib-OtBu as a white foam, which was used directly
in the next step.
Z-Leu-Aib-OH9 (0.375 g, 1.07 mmol) was coupled with H-Phe-Aib-OtBu (0.328
g, 1.07 mmol), using PyAOP (0.56 g, 1.1 mmol) and DIEA (0.276 g, 2.14 mmol)
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in abs. CH2Cl2 (10 ml) according to GP B. Reaction time: 20 h at rt. Purification
by CC (SiO2, EtOAc/hexane 20:1) yielded 0.556 g (81%) of tetrapeptide 4 as a
white foam. IR: 3325s, 3064w, 3032m, 2979m, 2960m, 2936m, 2872w, 1735s,
1665s, 1535s, 1469m , 1455m , 1385m , 1367m, 1258s, 1222s, 1148s, 1081w,
1029m, 940w, 850w, 788w, 752m, 698m. 1H-NMR (CD3OD): 7.34-7.16 (m, 10
arom. H); 5.12 (s, PhCH2O); 4.48-4.46, 4.05-3.95 (2m, CH(2) of Leu and CH(2)
of Phe); 3.32-3.29 (m, 1 H of CH2(3) of Phe); 2.94 (dd, J = 14.2, 10.6, 1 H of
CH2(3) of Phe); 1.80-1.51 (m, CH2(3) and CH(4) of Leu); 1.44, 1.43, 1.32, 1.16
(4s, 4 Me of 2 Aib and Me3C); 0.96, 0.92 (2d, J = 6.6, 2 Me(5) of Leu). 
13C-NMR
(CD3OD): 176.4, 175.3, 174.9, 172.5 (4s, 4 CO); 158.9 (s, CO (urethane)); 139.1,
137.9 (2s, 2 arom. C); 130.1, 129.4, 129.3, 129.0, 128.6, 127.5 (6d, 10 arom. CH);
81.9 (s, Me3C); 67.7 (t, PhCH2O); 57.7, 57.6 (2s, 2 C(2) of 2 Aib); 55.9 (d, C(2)
of Phe); 41.3, 37.8 (2t, C(3) of Phe and C(3) of Leu); 28.1 (q, Me3C); 25.7 (d,
C(4) of Leu); 25.4, 24.9, 24.7, 23.1, 22.1 (5q, 4 Me of 2 Aib and 2 Me(5) of Leu);
C(2) of Leu not detectable. ESI-MS (NaI+MeOH): 661 (100, [M+Na]+). Anal.
calc. for C35H50N4O7 (638.80): C 65.81, H 7.89, N 8.77; found: C 65.66, H 8.04,
N 8.70.
4.2.3. tert-Butyl N-[(Benzyloxy)carbonyl]-glycyl-dimethylglycyl-(S)-leucyl-
dimethylglycyl-(S)-phenylalanyl-dimethylglycinate (Z-Gly-Aib-Leu-Aib-Phe-
Aib-OtBu) (5).
Z-Leu-Aib-Phe-Aib-OtBu (4) (0.527 g, 0.82 mmol) was N-deprotected according
to GP A (H2, 55 mg Pd/C, 10 ml MeOH, overnight). The crude product was
filtered through a short SiO2-column with EtOAc/MeOH (17:1) and dried under
vacuum to afford 0.4 g (96%) of H-Leu-Aib-Phe-Aib-OtBu as a white foam. This
material (0.4 g, 0.79 mmol) was coupled with Z-Gly-Aib-OH7 (0.234 g, 0.79
mmol) by following GP B, using PyAOP (0.521 g, 1.0 mmol) and DIEA (0.255 g,
1.6 mmol) in abs. CH2Cl2 (10 ml). Reaction time: 20 h at rt. CC (SiO2,
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EtOAc/hexane/MeOH 10:7:1) gave 0.576 g (93%) of hexapeptide 5 as a white
foam. IR: 3322s, 3065w, 3033w, 2982m, 2959m, 2873w, 1664s, 1534s, 1456m,
1387m, 1368m, 1261m, 1151s, 1082w, 1051w, 979w, 852s, 740w, 699m. 1H-NMR
(CD3OD): 7.35-7.15 (m, 6 arom. H); 5.17-5.05 (m, PhCH2O); 4.42-4.39, 4.15-
3.70 (2m, CH(2) of Phe, CH(2) of Leu and CH2(2) of Gly); 3.35-2.80 (m, CH2(3)
of Phe); 1.90-1.47 (m, CH2(3) and CH(4) of Leu); 1.45, 1.44, 1.38, 1.18 (4s, 6 Me
of 3 Aib and Me3C); 0.94, 0.89 (2d , J = 6.3, 2 Me(5) of Leu). 
13C-NMR
(CD3OD): 177.1, 177.0, 174.9, 174.5, 172.8, 172.1 (6s, 6 CO); 159.5 (s, CO
(urethane)); 139.3, 137.9 (2s, 2 arom. C); 130.1, 129.5, 129.3, 129.1, 128.6, 127.5
(6d, 10 arom. CH); 81.8 (s, Me3C); 67.8 (t, PhCH2O); 57.9, 57.8, 57.7 (3s, 3 C(2)
of 3 Aib); 56.5, 54.1 (2d, C(2) of Phe and C(2) of Leu); 45.4, 39.9, 37.5 (3t, C(2)
of Gly, C(3) of Phe and C(3) of Leu); 28.1 (q, Me3C); 26.1 (d, C(4) of Leu); 26.5,
26.0, 25.9, 25.5, 24.9, 24.3, 23.7, 21.5 (8q, 6 Me of 3 Aib and 2 Me(5) of Leu).
ESI-MS (NaI + MeOH): 804 (100, [M+Na]+).
4.2.4. Cyclo(Gly1-Aib2-Leu3-Aib4-Phe5-Aib6) (1).
Z-Gly-Aib-Leu-Aib-Phe-Aib-OtBu (5) (0.555 g, 0.71 mmol) was N-deprotected
according to GP A (H2, 60 mg Pd/C, 10 ml MeOH, 20 h). Thus, 0.417 g (91 %) of
H-Gly-Aib-Leu-Aib-Phe-Aib-OtBu were obtained as a white foam, which was
dissolved in  abs. CH2Cl2 (20 ml), and TFA (20 ml) was added at rt. The mixture
was stirred for 6 h. Excess TFA was removed under reduced pressure, followed
by addition and evaporation of two portions of CH2Cl2 (10 ml). Upon drying
under high vacuum, 0.461 g of the free linear hexapeptide were obtained as its
TFA salt in quantitative yield.
HATU-mediated cyclization: 0.121 g (0.17 mmol) of H-Gly-Aib-Leu-Aib-Phe-
Aib-OH•TFA were dissolved in abs. DMF (112 ml) and subjected to cyclization
according to GP C, with HATU (0.194 g, 0.51 mmol), HOAt (69 mg, 0.51 mmol),
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and DIEA (1.2 ml). Reaction time: 1 d. Purification by CC (SiO2, CH2Cl2/MeOH
10:1, EtOAc/MeOH 15:1) afforded 23 mg (24%) of pure cyclohexapeptide 1.
DEPC-mediated cyclization: 0.121 g (0.17 mmol) of the free linear peptide TFA
salt were dissolved in abs. DMF (112 ml) and the cyclization was performed
according to GP D using DEPC (0.139 g, 0.85 mmol) and DIEA (1.2 ml). After 2
and 4 d of stirring, additional DEPC (69 mg, 0.425 mmol) was added. Reaction
time: 6 d. The obtained yellow oil was purified by CC (SiO2, EtOAc/MeOH 15:1,
performed twice) to provide 51 mg (53%) of pure 1.
PyAOP-mediated cyclization: 0.121 g (0.17 mmol) of the free linear peptide TFA
salt were dissolved in abs. DMF (170 ml) and treated with PyAOP (0.441 g, 0.85
mmol), HOAt (0.116 g, 0.85 mmol), and DIEA (1.7 ml) following GP E.
Purification by CC (SiO2, CH2Cl2/MeOH 17:1, performed twice) afforded 30 mg
(31%) of pure 1. White powder. M.p. (dec.) 284-286 °C. IR: 3317s, 3061w,
2968m, 2871w, 1704m, 1650s, 1536s, 1457m, 1390m, 1367m, 1264m, 1219m,
1188m, 1080w, 1029w, 744w, 698m. 1H-NMR: 8.22 (s, NH of Aib2); 8.05 (s, NH
of Aib6); 7.80 (d, J = 8.9, NH of Leu3); 7.62 (d, J = 7.6, NH of Phe5); 7.55 (s, NH
of Aib4); 7.27-7.16 (m, 5 arom. H of Phe5, NH of Gly1); 4.33-4.27 (m, CH(2) of
Leu3 and CH(2) of Phe5); 3.77 (dd, J = 17.0, 5.8, 1 H of CH2(2) of Gly
1); 3.70
(dd, J = 17.0, 3.2, 1 H of CH2(2) of Gly
1); 2.94 (dd, J = 13.5, 7.7, 1 H of CH2(3)
of Phe5); 2.85 (dd, J = 13.5, 7.2, 1 H of CH2(3) of Phe
5); 1.62-1.47 (m, CH2(3)
and CH(4) of Leu3); 1.46, 1.38 (2s, 2 Me of Aib4); 1.37, 1.29 (2s, 2 Me of Aib2);
1.26, 1.19 (2s, 2 Me of Aib6); 0.88, 0.82 (2d, J = 6.4, 2 Me(5) of Leu3). 13C-NMR:
174.2 (s, CO of Aib4); 174.0 (s, CO of Aib2); 173.7 (s, CO of Aib6); 171.3 (s, CO
of Leu3); 170.0 (s, CO of Phe5); 168.2 (s, CO of Gly1); 137.7 (s, 1 arom. C of
Phe5); 129.3, 128.0, 126.2 (3d, 5 arom. CH of Phe5); 56.4 (s, C(2) of Aib4); 56.2
(s, C(2) of Aib2); 56.0 (s, C(2) of Aib6); 55.1 (d, C(2) of Phe5); 50.9 (d, C(2) of
Leu3); 42.8 (t, C(2) of Gly1); 40.2 (t, C(3) of Leu3); 36.6 (t, C(3) of Phe5); 27.0 (q,
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1 Me of Aib6); 26.9 (q, 1 Me of Aib2); 25.9 (q, 1 Me of Aib4); 24.3 (d, C(4) of
Leu3); 23.47 (q, 1 Me of Aib2); 23.38 (q, Me(5) of Leu3); 23.14 (q, 1 Me of Aib4);
23.09 (q, 1 Me of Aib6); 21.1 (q, Me(5) of Leu3). ESI-MS (NaI + MeOH): 595
(100, [M+Na]+). Anal. calc. for C29H44N6O6 (572.71): C 60.82, H 7.74, N 14.67;
found: C 60.60, H 7.73, N 14.56.
4.3. Preparation of Cyclo(Leu-Aib-Phe-Gly-Aib-Aib) (2).
4 . 3 . 1 .  tert-Butyl N-[(Benzyloxy)carbonyl]-(S)-leucyl-dimethylglycyl-(S)-
phenylalaninate (Z-Leu-Aib-Phe-OtBu) (6).
Z-Leu-Aib-OH9 (0.25 g, 0.71 mmol) was coupled with HCl•H-Phe-OtBu (0.202
g, 0.78 mmol) in abs. CH2Cl2/MeCN (6 ml/2 ml) according to GP B, using
PyBOP (0.371 g, 0.71 mmol) and DIEA (0.276 g, 2.14 mmol, overnight).
Purification of the crude product by CC (SiO2, CH2Cl2/MeOH 17:1, performed
twice) afforded 0.362 g (92%) of tripeptide 6 as a white foam. IR: 3401m, 3368m,
3237m, 3033w, 2973m, 2951m, 1870w, 1720s, 1663s, 1651s, 1515s, 1457m,
1439m, 1389w, 1367m, 1246s, 1220m , 1166m, 1118w, 1040m, 861w, 846w,
780w, 755w, 743w, 700m. 1H-NMR: 8.05 (br.s, NH of Aib); 7.52-7.48 (m, NH of
Leu and NH of Phe); 7.33-7.17 (m, 10 arom. H); 5.06-4.95 (m, PhCH2O), 4.34-
4.31, 4.00-3.97 (2m, CH(2) of Phe and CH(2) of Leu); 2.96-2.93 (m, CH2(3) of
Phe); 1.70-1.31 (m, CH2(3) and CH(4) of Leu, 2 Me of Aib and Me3C); 0.88-0.84
(m, 2 Me(5) of Leu). 13C-NMR: 173.6, 171.7, 170.1 (3s, 3 CO); 156.0 (s, CO
(urethane)); 137.2, 136.8 (2s, 2 arom. C); 129.0, 128.1, 127.9, 127.6, 127.4, 126.3
(6d, 10 arom. CH); 80.5 (s, Me3C); 65.2 (t, PhCH2O); 55.8 (s, C(2) of Aib); 54.2,
53.3 (2d, C(2) of Leu and C(2) of Phe); 40.0, 36.8 (2t, C(3) of Leu and C(3) of
Phe); 27.4 (q, Me3C); 24.0 (d, C(4) of Leu); 25.5, 23.8, 22.8, 21.4 (4q, 2 Me of
Aib and 2 Me(5) of Leu). ESI-MS (NaI+MeOH): 576 (100, [M+Na]+). Anal. calc.
for C31H43N3O6 (553.69): C 67.24, H 7.83, N 7.59; found: C 67.23, H 7.82, N
7.54.
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4.3.2. Benzyl N-((S)-1-{[(1,1-Dimethyl-2-{[1-(S)-benzyl-2-({2-[(1,1-dimethyl-2-
{[1,1-dimethyl-2-(methylphenylamino)-2-oxoethyl]amino}-2-oxoethyl)amino]-
2-oxoethyl}amino)-2-oxoethyl]amino}-2-oxoethyl)amino]oxomethyl}-3-
methylbutyl) carbamate (Z-Leu-Aib-Phe-Gly-Aib-Aib-N(Me)Ph) (8).
Z-Leu-Aib-Phe-OtBu (6) (0.7 g, 1.26 mmol) was dissolved in CH2Cl2 (15 ml),
TFA was added (15 ml), and the mixture was stirred for 6 h at rt. The solvent was
then evaporated and the crude product filtered through a short SiO2-column using
CH2Cl2/MeOH (12:1) to give 0.586 g (93%) of Z-Leu-Aib-Phe-OH as a white
foam, which was used directly in the next reaction.
Z-Gly-Aib-Aib-N(Me)Ph (7)7 (0.234 g, 0.5 mmol) was N-deprotected following
GP A (H2, 25 mg Pd/C, 6 ml MeOH, overnight). The crude product was dried
under vacuum to give 0.159 g (95%) of H-Gly-Aib-Aib-N(Me)Ph, which was
used in the next reaction step without further purification.
The coupling of Z-Leu-Aib-Phe-OH (0.215 g, 0.43 mmol) with H-Gly-Aib-Aib-
N(Me)Ph (0.159 g, 0.48 mmol) in abs. CH2Cl2 (6 ml) was achieved according to
GP B, using PyAOP (0.26 g, 0.5 mmol) and DIEA (0.129 g, 1.0 mmol,
overnight). Purification by CC (SiO2, CH2Cl2/MeOH 20:1) afforded 0.21 g (60%)
of hexapeptide 8 as a white foam. IR: 3309s, 3062w, 3032m, 2957m, 2872w,
1662s, 1594m, 1533s, 1455s, 1389m, 1364m, 1332m, 1266m, 1221m, 1173m,
1118m, 1091m, 1045w, 1028w, 922w, 741w, 704m. 1H-NMR (CD3OD): 7.40-7.16
(m, 15 arom. H); 5.14-4.99 (m, PhCH2O); 4.05-3.59 (m, CH(2) of Leu, CH(2) of
Phe and CH2(2) of Gly); 3.35-2.90 (m, MeN and CH2(3) of Phe); 1.75-1.46 (m,
CH2(3) and CH(4) of Leu, 4 Me of 2 Aib); 1.30, 1.27 (2s, 2 Me of Aib); 0.96-0.91
(m , 2 Me(5) of Leu). 13C-NMR (CD3OD): 177.0, 176.2, 176.1, 175.4, 174.4,
171.3 (6s, 6 CO (amide)); 158.5 (s, CO (urethane)); 139.3, 138.1 (2s, 3 arom. C);
130.2, 130.1, 129.9, 129.4, 129.0, 128.5, 128.4, 128.2, 127.6 (9d, 15 arom. CH);
67.6 (t, PhCH2O); 58.6, 58.3, 57.7 (3s, 3 C(2) of 3 Aib); 57.1, 55.3 (2d, C(2) of
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Leu and C(2) of Phe); 44.8, 41.3 (2t, C(3) of Leu and C(2) of Gly); 41.27 (q,
MeN); 36.4 (t, C(3) of Phe); 25.7 (d, C(4) of Leu); 26.3, 25.3, 24.7, 23.2, 22.1
(5q, 6 Me of 3 Aib and 2 Me(5) of Leu). ESI-MS (NaI+MeOH): 837 (100,
[M+Na]+). Anal. calc. for C44H59N7O8•1/3 H2O (819.99): C 64.45, H 7.33, N
11.96; found: C 64.35, H 7.36, N 11.96.
4.3.3. Cyclo(Leu1-Aib2-Phe3-Gly4-Aib5-Aib6) (2).
Peptide 8 (0.42 g, 0.52 mmol) was dissolved in MeCN (3 ml) and then 3 ml of 6N
HCl were added dropwise. The mixture was stirred at rt overnight. The MeCN
was evaporated under reduced pressure and 2N HCl (3 ml) was added. The
product was extracted with CH2Cl2, the organic layer was dried (Na2SO4), filtered
and concentrated under reduced pressure. After drying under vacuum, 0.369 g
(98%) of Z-Leu-Aib-Phe-Gly-Aib-Aib-OH were obtained as a white foam. Then,
0.318 g (0.44 mmol) of this compound were N-deprotected according to GP A
(H2, 35 mg Pd/C, 6 ml MeOH, 20 h). After drying under vacuum, 0.241 g (93%)
of the free linear hexapeptide were obtained as a pale yellow foam, which was
used in the cyclization step without further purification.
HATU-mediated cyclization: 84 mg (0.14 mmol) of the free linear hexapeptide
were dissolved in abs. DMF (200 ml) and subjected to macrolactamization
according to GP C, with HATU (0.162 g, 0.43 mmol), HOAt (58 mg, 0.43 mmol),
and DIEA (2 ml). Reaction time: 3 d. Purification by CC (SiO2, CH2Cl2/MeOH
12:1, performed twice) afforded 13 mg (16 %) of pure cyclohexapeptide 2 as a
white foam.
DEPC-mediated cyclization: 88 mg (0.15 mmol) of the free linear precursor were
dissolved in abs. DMF (100 ml) and the cyclization was performed according to
GP D, using DEPC (0.141 g, 0.75 mmol) and DIEA (1 ml). After 2 and 4 d,
additional DEPC (60.5 mg, 0.375 mmol) was added to the stirred mixture.
Reaction time: 6 d. The obtained yellow oil was purified by CC (SiO2,
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CH2Cl2/MeOH 14:1, performed trice) to afford 28 mg (33%) of pure 2 as a white
foam.
PyAOP-mediated cyclization: 64 mg (0.11 mmol) of the free linear precursor
were dissolved in abs. DMF (180 ml) and treated with PyAOP (0.169 g, 0.32
mmol), HOAt (44 mg, 0.32 mmol) and DIEA (1.8 ml) by following GP E.
Purification by CC (SiO2, CH2Cl2/MeOH 12:1, performed thrice) yielded 30 mg
(48%) of pure 2 as a white foam. IR: 3327s, 3030w, 2957m, 2871w, 1657s, 1534s,
1469m, 1455m, 1385m, 1365m, 1277m, 1225m, 1179m, 1030w, 945w, 820w,
748w, 702m. 1H-NMR: 8.28 (s, NH of Aib5); 8.14 (s, NH of Aib2); 7.43 (br.s, NH
of Gly4); 7.41 (d, J = 9.7, NH of Leu1); 7.39 (s, NH of Aib6); 7.32 (d, J = 9.0, NH
of Phe3); 7.24-7.14 (m, 5 arom. H of Phe3); 4.59-4.55 (m, CH(2) of Phe3); 4.28-
4.20 (m, CH(2) of Leu1 and 1 H of CH2(2) of Gly
4); 3.62-3.59 (m, 1 H of CH2(2)
of Gly4); 3.31-3.28 (m, 1 H of CH2(3) of Phe
3); 2.93-2.89 (m, 1 H of CH2(3) of
Phe3); 1.88-1.83 (m, 1 H of CH2(3) of Leu
1); 1.72-1.68 (m, CH(4) of Leu1); 1.60-
1.55 (m, 1 H of CH2(3) of Leu
1); 1.43 (s, Me of Aib6); 1.31, 1.30 (2s, 2 Me of
Aib5); 1.23 (s, Me of Aib6); 1.12, 1.03 (2s, 2 Me of Aib2); 0.899, 0.897 (2d, J =
6.4, 6.8, 2 Me(5) of Leu1). 13C-NMR: 173.5 (s, CO of Aib2); 173.2 (s, CO of
Aib5); 173.0 (s, CO of Aib6); 172.9 (s, CO of Leu1); 170.7 (s, CO of Phe3); 169.1
(s, CO of Gly4); 138.6 (s, 1 arom. C of Phe3); 128.9, 127.9, 126.0 (3d, 5 arom. CH
of Phe3); 56.9 (s, C(2) of Aib6); 56.3 (s, C(2) of Aib5); 55.9 (s, C(2) of Aib2); 53.2
(d, C(2) of Phe3); 50.1 (d, C(2) of Leu1); 41.2 (t, C(2) of Gly4); 40.4 (t, C(3) of
Leu1); 35.5 (t, C(3) of Phe3); 28.0 (q, Me of Aib6); 26.1 (q, Me of Aib5); 25.7 (q,
Me of Aib2); 24.0 (d, C(4) of Leu1); 23.8 (q, Me(5) of Leu1); 23.7 (q, Me of Aib2);
23.22 (q, Me of Aib6); 23.19 (q, Me of Aib5); 20.9 (q, Me(5) of Leu1). ESI-MS
(NaI+MeOH): 595 (100, [M+Na]+). Anal. calc. for C29H44N6O6•1/2 H2O
(581.71): C 59.88, H 7.80, N 14.45; found: C 60.02, H 7.98, N 14.36.
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4.4.  X-Ray Crystal-Structure Determination of 1 and 2.
All measurements were made on a Nonius KappaCCD area-detector
diffractometer34 using graphite-monochromated MoKa radiation (λ 0.71073 Å)
and an Oxford Cryosystems Cryostream 700 cooler. The data collection and
refinement parameters are given below35 and views of the molecules are shown in
Figures 2 and 3. The intensities were corrected for Lorentz and polarization
effects, but not for absorption. Standard reflection intensities were not monitored.
Equivalent reflections, other than Friedel pairs, were merged. The structures were
solved by direct methods using SIR92,36 which revealed the positions of all non-
hydrogen atoms.
The iso-propyl part of the Leu side chain in 1 is disordered. Two positions were
defined for the disordered atoms and refinement of the site occupation factors
yielded a value of 0.53(2) for the major conformation. Bond length and similarity
restraints were applied to all chemically equivalent bond lengths and angles
involving the disordered atoms. Neighboring atoms within and between each
conformation of the disordered iso-propyl group were also restrained to have
similar atomic displacement parameters.
The asymmetric unit of 2 contains one molecule of the peptide plus two water
molecules, one disordered EtOH molecule and one disordered i-PrOH molecule.
Two positions were defined for each of the atoms of the two disordered solvent
molecules and the site occupation factors of the major conformations refined to
0.51(2) and 0.50(2) for the EtOH and i-PrOH molecules, respectively. Similarity
restraints were applied to the chemically equivalent bond lengths within the
disordered molecules and neighboring atoms within and between each
conformation of the disordered molecule were also restrained to have similar
atomic displacement parameters.
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The non-hydrogen atoms were refined anisotropically. The amide H-atoms in both
structures, and the water H-atoms in 2, were placed in positions indicated by a
difference electron density map and their positions were allowed to refine together
with individual isotropic displacement parameters. All remaining H-atoms were
placed in geometrically calculated positions and refined using a riding model
where each H-atom was assigned a fixed isotropic displacement parameter with a
value equal to 1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups). The
orientations of the hydroxy O-H vectors in the solvent molecules of 2 were chosen
so as to be directed towards the nearest hydrogen bond acceptor atom. The
refinement of each structure was carried out on F2 using full-matrix least-squares
procedures, which minimised the function Σw(Fo
2-Fc
2)2. Corrections for
secondary extinction were applied. For 1 and 2, eleven and two reflections,
respectively, were omitted from the final refinement. In each case, the enantiomer
used in the refinement was chosen to correspond with the known S-configuration
of the chiral centers derived from precursor molecules.
Neutral atom scattering factors for non-hydrogen atoms were taken from Ref. 37
and the scattering factors for H-atoms were taken from Ref. 38. Anomalous
dispersion effects were included in Fc;
39 the values for f’ and f’’ were those of Ref.
40. The values of the mass attenuation coefficients are those of Ref. 41. All
calculations were performed using the SHELXL97 program.42
In 1, each N-H group of the peptide molecule acts as a donor for hydrogen bonds.
Two of the interactions, N(1)-H and N(10)-H, are intramolecular hydrogen bonds.
N(1)-H interacts with the amide O(12)-atom that is diagonally opposed in the
peptide ring to give a loop with a graph set motif 43 of S(10). N(10)-H does not
interact with a diametrically opposed amide O-atom, but forms bifurcated
intramolecular hydrogen bonds with the amide O-atoms (O(6) and O(12), resp.) of
the two adjacent peptide units. These two interactions have graph set motifs of
25
S(7) and S(5). N(4)-H forms an intermolecular hydrogen bond with the amide O-
atom of the same peptide unit of a neighboring molecule and thereby links the
molecules into extended chains which run parallel to the [010] direction and have
a graph set motif of C(4). N(7)-H, N(13)-H and N(16)-H form intermolecular
hydrogen bonds with amide O-atoms of almost diagonally opposed peptide units
from three different neighboring molecules. Each of these interactions links the
molecules into extended chains which run parallel to the [010] direction and have
a graph set motif of C(10). Together, the intermolecular hydrogen bonds link the
molecules into extended two-dimensional networks which lie parallel to the (001)
plane.
In 2, all available N-H and O-H donors in the structure are involved in hydrogen
bonds. The peptide molecule has two intramolecular hydrogen N-H...O bonds
which diagonally cross the molecule to link the amide N-H donors with amide O-
atoms that are seven atoms further along the peptide backbone. Each of these
interactions has a graph set motif of S(10), which, despite the cyclic nature of the
peptide, is the same as usually observed in open chain peptides. The remaining
four amide N-H donors form intermolecular hydrogen bonds with the O-atoms
from each of the four symmetry-independent solvent molecules, so that the two
water molecules, the EtOH molecule and the i-PrOH molecule each accept one
hydrogen bond. Each of the solvent O-H donors, in turn, forms an intermolecular
hydrogen bond with an amide O-atom of a peptide molecule. The EtOH and i-
PrOH molecules both act as acceptors and donors of hydrogen bonds involving
the same peptide molecule to give a closed trimeric system. In each case, this
builds a loop with a graph set motif of R22(10). In contrast, the water molecules
form hydrogen bonds between different peptide molecules and thereby link all of
the peptide and solvent molecules in the structure into an infinite three-
dimensional framework. Although there are two symmetry-independent water
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molecules in the structure, each generates the same hydrogen bonding pattern.
The path via one H-atom from each water molecule creates a chain with a binary
graph set motif of C22(7), while the path via the other H-atom from each water
molecule creates a chain with a binary graph set motif of C22(10).
Crystal data for 1: C29H44N6O6, M = 572.70, colorless, prism, crystal dimensions
0.10 × 0.12 × 0.25 mm, orthorhombic, space group P212121, Z = 4, reflections for
cell determination 3164, 2θ range for cell determination 4 – 50°, a = 9.7189(2) Å,
b = 10.0614(2) Å, c = 31.9151(7) Å, V = 3120.8(1) Å3, T = 160 K, DX = 1.219
g⋅cm–3, µ(MoKα) = 0.0863 mm
–1, 2θ(max) = 50°, total reflections measured 27778,
symmetry independent reflections 3146, reflections with I >  2σ(I) 2265,
reflections used in refinement 3135, parameters refined 433; restraints 68, R(F) [I
> 2σ(I) reflections] = 0.0407, wR(F2) [all data] = 0.0870 (w = [σ 2(Fo
2) +
(0.0332P)2]–1, where P  = (F o
2+2Fc
2)/3), goodness of fit 1.000, secondary
extinction coefficient 0.005(1), final Δmax/σ 0.001, Δρ (max; min) = 0.18; –0.18 e
Å–3.
Crystal data for 2: C29H44N6O6•EtOH•i-PrOH•2H2O, M  = 714.89, colorless,
prism, crystal dimensions 0.30 × 0.30 × 0.35 mm, monoclinic, space group P21, Z
= 2, reflections for cell determination 4747, 2θ range for cell determination 4 –
55°, a = 10.0827(1) Å, b = 12.5382(1) Å, c = 15.7976(2) Å, β = 96.4866(4)°, V =
1984.33(4) Å3, T = 160 K, DX = 1.196 g⋅cm
–3, µ(MoKα) = 0.0878 mm
–1, 2θ(max) =
55°, total reflections measured 44105, symmetry independent reflections 4757,
reflections with I > 2σ(I) 4044, reflections used in refinement 4755, parameters
refined 573; restraints 164, R(F) [I > 2σ(I) reflections] = 0.0459, wR(F2) [all data]
= 0.1280 (w = [σ2(Fo
2) + (0.0817P)2 + 0.2355P]–1, where P  = (F o
2+2Fc
2)/3),
goodness of fit 1.040, secondary extinction coefficient 0.025(4), final Δmax/σ
0.001, Δρ (max; min) = 0.42; –0.29 e Å–3.
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Captions:
Fig. 1. Selected ROESY correlations for compounds 1 and 2 in DMSO-d6
Fig. 2.  ORTEP Plot23 of the molecular structure of 1 (50% Probability ellipsoids,
arbitrary numbering of atoms, only one of the disordered arrangements of the Leu
side chain is shown)
Fig. 3.  ORTEP Plot23 of the molecular structure of 2 (50% Probability ellipsoids,
arbitrary numbering of atoms, solvent molecules omitted for clarity)
Fig. 4. Superimposition of the final 14 NMR structures for 1
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Table 1. Conditions used for the cyclization of Aib-containing hexapeptides 5 and 8
Cyclic peptide Cyclization method Reaction time Yield
HATU / HOAt (3 eq) 1 d 24%
PyAOP / HOAt (5 eq) 3 d 31%
Cyclo(Gly-Aib-Leu-Aib-Phe-Aib)
1
DEPC (10 eq) 6 d 53%
HATU / HOAt (3 eq) 3 d 16%
DEPC (10 eq) 6 d 33%
Cyclo(Leu-Aib-Phe-Gly-Aib-Aib)
2
PyAOP /HOAt (3 eq) 3 d 48%
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Table 2. Backbone torsion angles [°] for the crystal structures of 1 and 2
1 Gly1 Aib2 Leu3 Aib4 Phe5 Aib6
φ -170.0(3) +55.2(3) -90.7(3) -175.9(3) -45.4(4) +76.9(4)
ψ +119.6(3) -130.4(3) +42.6(3) +178.6(2) +127.2(3) -7.7(4)
ω +178.2(2) -164.7(2) +166.1(2) -171.8(2) +169.1(2) -178.1(3)
2 Leu1 Aib2 Phe3 Gly4 Aib5 Aib6
φ -113.0(3) -57.1(3) -113.3(3) +117.8(3) +56.4(3) +93.8(3)
ψ -171.7(2) -34.4(3) +22.8(3) +169.4(2) +41.2(3) -15.3(3)
ω -165.6(2) -171.4(2) -178.3(2) +170.3(2) +172.5(2) -173.8(2)
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Table 3. Hydrogen bonding parameters for cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1)
Donor
D-H
Acceptor
A
Distance [Å]
D-H
Distance [Å]
H...A
Distance [Å]
D...A
Angle [°]
D-H...A
N(1)-H(1) O(12) 0.81(3) 2.34(3) 3.126(4) 163(3)
N(4)-H(4) O(3i) 0.84(3) 2.30(3) 3.131(4) 172(3)
N(7)-H(7) O(18ii) 0.94(3) 2.00(3) 2.877(3) 154(3)
N(10)-H(10) O(12) 0.83(3) 2.17(3) 2.604(3) 113(3)
N(10)-H(10) O(6) 0.83(3) 2.38(3) 3.083(3) 143(3)
N(13)-H(13) O(6iii) 0.87(3) 2.11(3) 2.972(3) 171(3)
N(16)-H(16) O(9iv) 0.94(3) 1.95(4) 2.867(3) 163(3)
Primed atoms refer to the molecule in the following symmetry-related positions: i 2-x, -1/2+y, 1/2-z; ii 2-x,
1/2+y, 1/2-z; iii 1-x, 1/2+y, 1/2-z; iv 1-x, -1/2+y, 1/2-z.
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Table 4. Hydrogen bonding parameters for cyclo(Leu-Aib-Phe-Gly-Aib-Aib) (2)
Donor
D-H
Acceptor
A
Distance [Å]
D-H
Distance [Å]
H...A
Distance [Å]
D...A
Angle [°]
D-H...A
N(1)-H(1) O(12) 0.87(4) 2.24(4) 3.042(3) 154(3)
N(4)-H(4) O(44i) 0.89(4) 1.90(4) 2.782(3) 171(3)
N(7)-H(7) O(38a) 0.89(4) 2.21(4) 2.92(1) 136(3)
N(7)-H(7) O(38b) 0.89(4) 2.18(4) 2.87(1) 135(3)
N(10)-H(10) O(3) 0.93(4) 2.18(4) 3.078(3) 161(3)
N(13)-H(13) O(43) 0.88(4) 1.91(4) 2.787(3) 176(3)
N(16)-H(16) O(42a) 0.73(3) 2.48(3) 3.10(1) 145(3)
N(16)-H(16) O(42b) 0.73(3) 2.38(3) 2.99(1) 141(3)
O(38a)-H(381) O(12) 0.84 1.91 2.75(2) 173
O(38b)-H(382) O(12) 0.84 2.26 2.87(2) 129
O(42a)-H(421) O(3) 0.84 2.15 2.79(2) 132
O(42b)-H(422) O(3) 0.84 1.96 2.74(2) 154
O(43)-H(431) O(15ii) 0.98(6) 1.83(6) 2.805(3) 174(4)
O(43)-H(432) O(18iii) 0.79(5) 1.96(5) 2.750(3) 177(4)
O(44)-H(441) O(6iv) 0.87(6) 1.89(6) 2.754(3) 171(5)
O(44)-H(442) O(9) 0.95(5) 1.80(5) 2.734(3) 168(4)
Primed atoms refer to the molecule in the following symmetry-related positions: i –1+x, y, z; ii 1-x, -1/2+y, 2-
z; iii 1+x, y, z; iv 1-x, 1/2+y, 1-z.
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Table 5. Observed average backbone torsion angles for the cyclic peptide 1 as obtained from the
molecular dynamics simulation
Residue φ ψ
Gly1 -105.2 +170.0
Aib2 -63.8 -26.5
Leu3 -123.6 +31.2
Aib4 -162.9 -165.3
Phe5 -84.6 +88.1
Aib6 +80.9 +21.1
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Table 6. Intraresidual upper distance restraints derived from integration of ROESY cross-peak
volumes for the cyclic peptide cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1)
Residue Atom Residue Atom Distance [Å]
Gly1 HN Gly1 HA1 2.87
Leu3 HN Leu3 HB2 2.77
Leu3 HA Leu3 HB2 2.68
Leu3 HA Leu3 HB3 2.62
Leu3 HA Leu3 QD1 3.64
Leu3 HA Leu3 QD2 5.69
Phe5 HN Phe5 HA 2.83
Phe5 HN Phe5 HB2 2.99
Phe5 HN Phe5 HB3 3.27
Phe5 HA Phe5 HB2 2.65
Phe5 HA Phe5 HB3 2.71
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Table 7. Sequential upper distance restraints derived from integration of ROESY cross-peak
volumes for the cyclic peptide cyclo(Gly-Aib-Leu-Aib-Phe-Aib) (1)
Residue Atom Residue Atom Distance [Å]
Gly1 HN Aib2 HN 4.69
Gly1 HN Aib6 HN 3.24
Gly1 HN Aib6 QB1 4.74
Gly1 HN Aib6 QB2 5.34
Gly1 HA1 Aib2 HN 2.83
Gly1 HA2 Aib2 HN 2.71
Aib2 HN Leu3 HN 3.42
Aib2 QB1 Leu3 HN 4.55
Aib2 QB1 Leu3 HA 6.38
Aib2 QB1 Leu3 QD1 7.56
Aib2 QB1 Leu3 QD2 7.56
Aib2 QB2 Leu3 QD1 7.57
Aib2 QB2 Leu3 QD2 7.57
Leu3 HN Aib4 HN 3.11
Leu3 HA Aib4 HN 2.62
Leu3 HA Aib4 QB1 5.88
Leu3 HB2 Aib4 HN 3.79
Leu3 HB3 Aib4 HN 3.83
Aib4 QB1 Phe5 HA 6.04
Aib4 QB1 Phe5 QD 8.66
Aib4 QB2 Phe5 HN 4.10
Aib4 QB2 Phe5 QD 8.67
Phe5 HN Aib6 HN 4.07
Phe5 HA Aib6 HN 2.40
Phe5 HA Aib6 QB2 6.54
Phe5 HB2 Aib6 HN 4.82
Phe5 HB3 Aib6 HN 4.29
Phe5 QD Aib6 QB2 8.29
Phe5 QE Aib6 QB2 8.67
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Table 8. Medium and long range upper distance restraints derived from integration of ROESY
cross-peak volumes for the cyclic peptide 1.
Residue Atom Residue Atom Distance [Å]
Gly1 HN Aib4 HN 4.20
Gly1 HN Aib4 HB1 5.73
Gly1 HN Phe5 HN 4.14
Gly1 HN Phe5 HA 3.61
Aib4 QB1 Aib6 HN 6.54
40
HNN
H
HN
H
NNH
NH
O
O
O
O
O
O
H
H
HNN
H
HN
H
NNH
NH
O
O
O
O
O
O
H
H
Fig. 1. Selected ROESY correlations for compounds 1 and 2 in DMSO-d6
1 2
41
Fig. 2. ORTEP Plot 23 of the molecular structure of 1 (50% Probability ellipsoids,
arbitrary numbering of atoms, only one of the disordered arrangements of the Leu
side chain is shown)
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Fig. 3. ORTEP Plot 23 of the molecular structure of 2 (50% Probability ellipsoids,
arbitrary numbering of atoms, solvent molecules omitted for clarity)
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Fig. 4. Superimposition of the final 14 NMR structures for 1
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